> Detailanzeige

Hoffmann, Emily; Schache, Daniel; Höltke, Carsten; Soltwisch, Jens; Niland, Stephan; Krähling, Tobias; Bergander, Klaus; Grewer, Martin; Geyer, Christiane; Groeneweg, Linda; Eble, Johannes A.; Vogl, Thomas; Roth, Johannes; Heindel, Walter; Maus, Bastian; Helfen, Anne; Faber, Cornelius; Wildgruber, Moritz; Gerwing, Mirjam; Hoerr, Verena

Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy
  • Beteiligte: Hoffmann, Emily; Schache, Daniel; Höltke, Carsten; Soltwisch, Jens; Niland, Stephan; Krähling, Tobias; Bergander, Klaus; Grewer, Martin; Geyer, Christiane; Groeneweg, Linda; Eble, Johannes A.; Vogl, Thomas; Roth, Johannes; Heindel, Walter; Maus, Bastian; Helfen, Anne; Faber, Cornelius; Wildgruber, Moritz; Gerwing, Mirjam; Hoerr, Verena
  • Erschienen: Springer Science and Business Media LLC, 2023
  • Erschienen in: Journal of Translational Medicine, 21 (2023) 1
  • Sprache: Englisch
  • DOI: 10.1186/s12967-023-04451-6
  • ISSN: 1479-5876
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Background With metabolic alterations of the tumor microenvironment (TME) contributing to cancer progression, metastatic spread and response to targeted therapies, non-invasive and repetitive imaging of tumor metabolism is of major importance. The purpose of this study was to investigate whether multiparametric chemical exchange saturation transfer magnetic resonance imaging (CEST-MRI) allows to detect differences in the metabolic profiles of the TME in murine breast cancer models with divergent degrees of malignancy and to assess their response to immunotherapy. Methods Tumor characteristics of highly malignant 4T1 and low malignant 67NR murine breast cancer models were investigated, and their changes during tumor progression and immune checkpoint inhibitor (ICI) treatment were evaluated. For simultaneous analysis of different metabolites, multiparametric CEST-MRI with calculation of asymmetric magnetization transfer ratio (MTRasym) at 1.2 to 2.0 ppm for glucose-weighted, 2.0 ppm for creatine-weighted and 3.2 to 3.6 ppm for amide proton transfer- (APT-) weighted CEST contrast was conducted. Ex vivo validation of MRI results was achieved by 1H nuclear magnetic resonance spectroscopy, matrix-assisted laser desorption/ionization mass spectrometry imaging with laser postionization and immunohistochemistry. Results During tumor progression, the two tumor models showed divergent trends for all examined CEST contrasts: While glucose- and APT-weighted CEST contrast decreased and creatine-weighted CEST contrast increased over time in the 4T1 model, 67NR tumors exhibited increased glucose- and APT-weighted CEST contrast during disease progression, accompanied by decreased creatine-weighted CEST contrast. Already three days after treatment initiation, CEST contrasts captured response to ICI therapy in both tumor models. Conclusion Multiparametric CEST-MRI enables non-invasive assessment of metabolic signatures of the TME, allowing both for estimation of the degree of tumor malignancy and for assessment of early response to immune checkpoint inhibition.
  • Zugangsstatus: Freier Zugang